CollPlant Biotechnologies (NASDAQ:CLGN) Earns “Buy” Rating from D. Boral Capital
CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $14.00 price objective on the stock. D. Boral Capital’s price target would indicate a potential upside of 449.02% from the company’s previous close. Separately, HC […]
CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $14.00 price objective on the stock. D. Boral Capital’s price target would indicate a potential upside of 449.02% from the company’s previous close. Separately, HC […]
